AbbVie reported third quarter 2026 results that exceeded analyst expectations for both revenue and adjusted earnings. Growth was primarily driven by the continued expansion of the immunology and neuroscience franchises, which more than offset the expected double-digit decline in Humira sales following biosimilar entry.
Key Highlights
- Immunology revenue rose 16.3% to $9.17 billion, anchored by $5.78 billion from Skyrizi and $2.71 billion from Rinvoq.
- Neuroscience portfolio revenue grew 19.4% to $3.39 billion, supported by billion-dollar quarters from both Vraylar and Botox Therapeutic.
- Management raised full-year 2026 adjusted EPS guidance to a range of $13.95–$13.99 and declared a 5.2% dividend increase to $1.82 per share.
- Humira global net revenues fell 31.2% to $683 million, reflecting the ongoing erosion of the legacy asset.